2017

Title	Date
INmune Bio Appoints Edgardo Baracchini to its Board of Directors, Gains Additional Licensing and Business Development Expertise	16 Oct, 2017
INmune Bio to Present at the BIO Investor 2017 Healthcare Conference	11 Oct, 2017
INmune Bio Licenses INB03, a First-in Class Innate Immune System Check-Point Inhibitor that Targets Myeloid Derived Suppressor Cells in Cancer	10 Oct, 2017
INmune Bio Licenses Technology to Deplete Myeloid Derived Suppressor Cells of the Innate Immune System in Patients with Cancer	09 Oct, 2017
INmune Bio Adds Clinical Development and Product Development Expertise with the Appointment of Tim Schroeder to its Board of Directors	26 Sep, 2017
INmune Bio Co-Founder, Professor Mark Lowdell, Named One of Europe’s Academic-Entrepreneur Superstars	01 Mar, 2017